Decreased In Vitro Susceptibility of Plasmodium falciparum Isolates to Artesunate, Mefloquine, Chloroquine, and Quinine in Cambodia from 2001 to 2007

Institut Pasteur in Cambodia, Molecular Epidemiology Unit, Phnom Penh, Cambodia.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.48). 03/2010; 54(5):2135-42. DOI: 10.1128/AAC.01304-09
Source: PubMed


This study describes the results of in vitro antimalarial susceptibility assays and molecular polymorphisms of Plasmodium falciparum isolates from Cambodia. The samples were collected from patients enrolled in therapeutic efficacy studies (TES) conducted by the Cambodian National Malaria Control Program for the routine efficacy monitoring of artemisinin-based combination therapy (ACT) (artesunate-mefloquine and artemether-lumefantrine combinations). The isolates (n = 2,041) were obtained from nine sentinel sites during the years 2001 to 2007. Among these, 1,588 were examined for their in vitro susceptibilities to four antimalarials (artesunate, mefloquine, chloroquine, and quinine), and 851 isolates were genotyped for single nucleotide polymorphisms (SNPs). The geometric means of the 50% inhibitory concentrations (GMIC(50)s) of the four drugs tested were significantly higher for isolates from western Cambodia than for those from eastern Cambodia. GMIC(50)s for isolates from participants who failed artesunate-mefloquine therapy were significantly higher than those for patients who were cured (P, <0.001). In vitro correlation of artesunate with the other drugs was observed. The distributions of the SNPs differed between eastern and western Cambodia, suggesting different genetic backgrounds of the parasite populations in these two parts of the country. The GMIC(50)s of the four drugs tested increased significantly in eastern Cambodia during 2006 to 2007. These results are worrisome, because they may signal deterioration of the efficacy of artesunate-mefloquine beyond the Cambodian-Thai border.

26 Reads
  • Source
    • "Malaria is an important health problem, responsible for 219 million clinical cases and 660,000 deaths in 2010 [1]. A major obstacle to the eradication of this disease is the emerging resistance of the malaria-causing parasite Plasmodium falciparum to most marketed antimalarial drugs [2] [3]. As such, new compounds acting through novel mechanisms of action are urgently needed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: An in vitro investigation of the antiplasmodial and cytotoxic activities of a series of human choline kinase inhibitors against Plasmodium falciparum is reported. Structure-activity relationship analyses have allowed us to determine the essential parameters for the antimalarial effect of these asymmetrical pyridinium derivatives. One of the compounds meets the World Health Organization's criteria for hit identification against P. falciparum exhibiting an IC50 of 0.0016 μg/ml and a selectivity index of >3000.
    European Journal of Medicinal Chemistry 10/2014; 85:289–292. DOI:10.1016/j.ejmech.2014.07.105 · 3.45 Impact Factor
  • Source
    • "Importantly, resistance to PQ was described some decades ago in China [30]. Although recent definitive evidence of resistance to PQ has not been reported in studies from Africa or Asia, ex vivo sensitivity to the drug has varied considerably, and careful continued surveillance of parasite susceptibility is important [31], [32], [33]. Reassuringly, treatment with DHA-PQ did not select for parasite polymorphisms that are associated with resistance to the related aminoquinolines chloroquine and amodiaquine [34]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: One promising new Artemisinin-based combination therapies (ACTs) is dihydroartemisinin-piperaquine (DHA-PQ). However, the pharmacokinetics of piperaquine and the relationship between drug levels and clinical efficacy are incompletely characterized, particularly in children.
    PLoS ONE 08/2014; 9(8):e103200. DOI:10.1371/journal.pone.0103200 · 3.23 Impact Factor
  • Source
    • "and 403.9 (330.50-493.54) nM, respectively], but was improved during 1997–2008 [18,36,37,39]. A total of 16 isolates were identified as QN resistance, 12 and four isolates collected during 2006–2007 and 2008–2009, respectively. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The decline in efficacy of artesunate (AS) and mefloquine (MQ) is now the major concern in areas along the Thai-Cambodian and Thai-Myanmar borders. The correlation between polymorphisms of pfatp6, pfcrt, pfmdr1 and pfmrp1 genes and in vitro sensitivity of Plasmodium falciparum isolates to the artemisinin-based combination therapy (ACT) components AS and MQ, including the previously used first-line anti-malarial drugs chloroquine (CQ) and quinine (QN) were investigated in a total of 119 P. falciparum isolates collected from patients with uncomplicated P. falciparum infection during 2006-2009. Reduced in vitro parasite sensitivity to AS [median (95% CI) IC50 3.4 (3.1-3.7) nM] was found in 42% of the isolates, whereas resistance to MQ [median (95% CI) IC50 54.1 (46.8-61.4) nM] accounted for 58% of the isolates. Amplification of pfmdr1 gene was strongly associated with a decline in susceptibility of P. falciparum isolates to AS, MQ and QN. Significant difference in IC50 values of AS, MQ and QN was observed among isolates carrying one, two, three, and >= four gene copies [median (95% CI) AS IC50: 1.6 (1.3-1.9), 1.8 (1.1-2.5), 2.9 (2.1-3.7) and 3.1 (2.5-3.7) nM, respectively; MQ IC50: 19.2 (15.8-22.6), 37.8 (10.7-64.8), 55.3 (47.7-62.9) and 63.6 (49.2-78.0) nM, respectively; and QN IC50: 183.0 (139.9-226.4), 256.4 (83.7-249.1), 329.5 (206.6-425.5) and 420.0 (475.2-475.6) nM, respectively]. The prevalence of isolates which were resistant to QN was reduced from 21.4% during the period 2006-2007 to 6.3% during the period 2008-2009. Pfmdr1 86Y was found to be associated with increased susceptibility of the parasite to MQ and QN. Pfmdr1 1034C was associated with decreased susceptibility to QN. Pfmrp1 191Y and 1390I were associated with increased susceptibility to CQ and QN, respectively. High prevalence of CQ and MQ-resistant P. falciparum isolates was observed during the four-year observation period (2006-2009). AS sensitivity was declined, while QN sensitivity was improved. Pfmdr1 and pfmrp1 appear to be the key genes that modulate multidrug resistance in P. falciparum.
    Malaria Journal 01/2014; 13(1):23. DOI:10.1186/1475-2875-13-23 · 3.11 Impact Factor
Show more